A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review (METER)
Status
Conditions
Details and patient eligibility
About
Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis.
Data from approximately 1000 participants will be collected. No participants will be enrolled in this study.
Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks.
There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Treated for myelofibrosis (MF) [primary myelofibrosis (PMF) and secondary myelofibrosis (SMF)].
- Must have initiated their first treatment on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.
Exclusion criteria
- Having received MF treatment in a clinical trial setting.
Trial design
998 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
ABBVIE CALL CENTER
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal